肿瘤综合治疗电子杂志2025，Vol.11Issue(6)：41-47,7.DOI:10.12151/JMCM.2025.06-06
替雷利珠单抗联合阿昔替尼对女性转移性肾癌患者血清肿瘤标志物、Klotho蛋白、白蛋白/碱性磷酸酶比值、全身炎症反应指数及预后的影响
Effect of tislelizumab combined with axitinib on serum tumor markers,Klotho protein,albumin/alkaline phosphatase ratio,systemic inflammation response index,and prognosis in female patients with metastatic renal cell carcinoma
摘要
Abstract
Objective To analyze the effect of tislelizumab combined with axitinib on serum tumor markers,Klotho protein,albumin/alkaline phosphatase ratio(AAPR),systemic inflammation response index(SIRI),and prognosis in female patients with metastatic renal cell carcinoma.Method A total of 80 patients with metastatic renal cell carcinoma admitted to Ganzhou Maternal and Child Health Hospital from January 2020 to July 2022 were retrospectively included.Patients received axitinib plus pembrolizumab were assigned to the control group(33 cases),while those received axitinib combined with tislelizumab were assigned to the observation group(47 cases).The short-term efficacy,adverse events,medium-term prognosis,and changes in serum tumor markers,Klotho protein,AAPR,and SIRI before and after treatment were compared between the two groups.Result After 6 weeks of treatment,the objective response rate(ORR),disease control rate(DCR),Klotho protein level,and AAPR in observation group were significantly higher than those in control group(all P＜0.05),and the levels of serum carcinoembryonic antigen(CEA),cytokeratin-19 fragment(CYFRA21-1),vascular endothelial growth factor(VEGF),matrix metalloproteinase-2(MMP-2),tissue inhibitor of metalloproteinase-1(TIMP-1),tumor necrosis factor-β1(TNF-β1),and SIRI were significantly lower than those in the control group(all P＜0.05).The incidence of hypothyroidism during treatment in observation group was significantly higher than that of control group(P＜0.05).The incidence of adverse events in the observation group and the control group were 95.74%and 81.82%,respectively,and the incidence of adverse events in grades 3-4 were 14.84%and 9.09%,respectively.There were no statistical differences between the two groups(all P＞0.05).The median progression-free survival time in the observation group was 13.00 months(95%CI:10.96-24.39),which was longer than that in the control group[9.5 months(95%CI:5.77-15.99)](Log-rank P=0.007).The median total survival time in the observation group was 36.0 months(95%CI:27.78-54.60),which was longer than that in the control group[20.0 months(95%CI:11.05-30.33)](Log-rank P=0.004).Conclusion Compared to axitinib combined with pembrolizumab,axitinib combined with tislelizumab can significantly improve the serum tumor marker profiles,short-term and medium-term efficacy within a manageable safety profile.The mechanism may be related to the regulatory effect of tislelizumab on Klotho protein,AAPR,and SIRI.关键词
替雷利珠单抗/阿昔替尼/转移性肾癌/肿瘤标志物/Klotho蛋白/白蛋白/碱性磷酸酶比值/全身炎症反应指数Key words
Tislelizumab/Axitinib/Metastatic renal cell carcinoma/Tumor markers/Klotho protein/Albumin/alkaline phosphatase ratio/Systemic inflammation response index引用本文复制引用
赵利珍,韩欢欢,卢辛辛,邱梅英,胡芳芳..替雷利珠单抗联合阿昔替尼对女性转移性肾癌患者血清肿瘤标志物、Klotho蛋白、白蛋白/碱性磷酸酶比值、全身炎症反应指数及预后的影响[J].肿瘤综合治疗电子杂志,2025,11(6):41-47,7.基金项目
江西省卫生健康委科技计划资助项目(202312012) （202312012）
